Search - tctmd.com

Displaying 841 - 860 of 1134

Sort: Relevancy | Date

News Daily News

Negative Statin-Related News Linked With Drug Discontinuation, Increased CV Risk

Michael O'Riordan

December 02, 2015

News Conference News AHA 2015

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

Todd Neale

November 12, 2015

News Conference News AHA 2015

Most Drug Discontinuations in PEGASUS-TIMI 54 Related to Dyspnea, Bleeding

Todd Neale

November 10, 2015

News Conference News AHA 2015

DAPT Score Provides ‘Personalized Medicine’ Tool for Determining Whether to Extend Therapy Beyond 1 Year

Yael L. Maxwell

November 09, 2015

News Conference News AHA 2015

CANOA: Fewer Migraines With Clopidogrel Plus Aspirin Post-ASD Closure

Shelley Wood

November 08, 2015

News Daily News

FDA: Long-Term Clopidogrel Neither Ups, Nor Cuts Risk of Death in CVD Patients

Yael L. Maxwell

November 08, 2015

News Daily News

Endovascular Therapy Beats Thrombolysis for Improving Function After Stroke

L.A. McKeown

November 03, 2015

News Daily News

ADAPT-DES Analysis Reopens Debate Over Possible PPI, Clopidogrel Interaction

Caitlin E. Cox

October 28, 2015

News Daily News

Goodbye BMS? New DAPT Analysis Shows Less Stent Thrombosis With DES

Yael L. Maxwell

October 26, 2015

News Industry News

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

October 20, 2015

News Conference News TCT 2015

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Yael L. Maxwell

October 15, 2015

News Industry News

Polymer-Free Drug-Coated vs. Bare-Metal Coronary Stents In High Bleeding Risk Patients With One Month DAPT

October 14, 2015

News Conference News TCT 2015

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Yael L. Maxwell

October 14, 2015

News Conference News TCT 2015

Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials

October 13, 2015

News Conference News TCT 2015

Discussion Highlights Merits, Limitations of Small Trials

Yael L. Maxwell

October 13, 2015

News Conference News TCT 2015

DAPT Study Subanalysis Focuses on EES Subgroup

October 12, 2015

News Conference News TCT 2015

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

October 11, 2015

News Daily News

Transradial PCI May Attenuate Bivalirudin Benefits

Todd Neale

October 05, 2015

News Industry News

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 28, 2015

News Daily News

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

L.A. McKeown

September 21, 2015

Advertisement

Negative Statin-Related News Linked With Drug Discontinuation, Increased CV Risk

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

Most Drug Discontinuations in PEGASUS-TIMI 54 Related to Dyspnea, Bleeding

DAPT Score Provides ‘Personalized Medicine’ Tool for Determining Whether to Extend Therapy Beyond 1 Year

CANOA: Fewer Migraines With Clopidogrel Plus Aspirin Post-ASD Closure

FDA: Long-Term Clopidogrel Neither Ups, Nor Cuts Risk of Death in CVD Patients

Endovascular Therapy Beats Thrombolysis for Improving Function After Stroke

ADAPT-DES Analysis Reopens Debate Over Possible PPI, Clopidogrel Interaction

Goodbye BMS? New DAPT Analysis Shows Less Stent Thrombosis With DES

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Polymer-Free Drug-Coated vs. Bare-Metal Coronary Stents In High Bleeding Risk Patients With One Month DAPT

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials

Discussion Highlights Merits, Limitations of Small Trials

DAPT Study Subanalysis Focuses on EES Subgroup

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

Transradial PCI May Attenuate Bivalirudin Benefits

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content